Published on June 9, 2014 | Category Product launch
Valtrex regains its patent right
Pharmapar wants to inform you that the pharmaceutical company Glaxo Smith Kline regained its patent right on Valtrex (Dom-Valacyclovir).
This is the reason why generics companies have stopped selling that molecule since June 1st 2014.
Therefore, it is not a stock shortage.
This new patent will expire by September 13th 2015 at the soonest, but that date still needs confirmation.
For any question or comment regarding that news, please feel free to contact your Pharmapar representative
Thank you for your trust in Pharmapar.